{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:04:50Z","timestamp":1784531090839,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119679","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:19:22Z","timestamp":1781723962000},"page":"119679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A six-proline stabilized trimeric spike DNA vaccine induces robust immunity and protects against SARS-CoV-2 delta challenge in K18-hACE2 transgenic mice"],"prefix":"10.1016","volume":"201","author":[{"given":"Ayt\u00fcl","family":"G\u00fcl-Mete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-5369","authenticated-orcid":false,"given":"Ceren","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"Karakavuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Karakavuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hivda","family":"\u00dclbe\u011fi-Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcge","family":"Serhatl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eenay","family":"K\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu Ta\u015f","family":"Ekiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem","family":"Abaci-Bayraktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"En\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumhur","family":"Ad\u0131ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Uzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahriye","family":"Sara\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysu","family":"De\u011firmenci D\u00f6\u015fkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y\u00fcksel","family":"G\u00fcr\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"D\u00f6\u015fkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Esin","family":"Hame\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119679_bib1","unstructured":"WHO, 2026a. WHO COVID-19 dashboard. \u3008https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c\u3009 Last assessed: 19.02.2026."},{"key":"10.1016\/j.biopha.2026.119679_bib2","unstructured":"WHO, 2026b. COVID-19 vaccine tracker. \u3008https:\/\/covid19.trackvaccines.org\/agency\/who\/\u3009 Last assessed: 19.02.2026."},{"issue":"3","key":"10.1016\/j.biopha.2026.119679_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/v15030624","article-title":"Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern","volume":"15","author":"Al-Fattah Yahaya","year":"2023","journal-title":"Viruses"},{"issue":"7883","key":"10.1016\/j.biopha.2026.119679_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biopha.2026.119679_bib5","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review","volume":"94","author":"Notarte","year":"2022","journal-title":"J. Med. Virol."},{"issue":"7871","key":"10.1016\/j.biopha.2026.119679_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119679_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118919","article-title":"DNA vaccines against COVID-19: Perspectives and challenges","volume":"267","author":"Silveira","year":"2021","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.advms.2023.05.003","article-title":"The development of DNA vaccines against SARS-CoV-2","volume":"68","author":"Khalid","year":"2023","journal-title":"Adv. Med. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119679_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/vaccines1030225","article-title":"Vector Design for Improved DNA Vaccine Efficacy, Safety and Production","volume":"1","author":"Williams","year":"2013","journal-title":"Vaccin. (Basel)"},{"issue":"10","key":"10.1016\/j.biopha.2026.119679_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/vaccines7020037","article-title":"A Comparison of Plasmid DNA and mRNA as Vaccine Technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccin. (Basel)"},{"issue":"30","key":"10.1016\/j.biopha.2026.119679_bib12","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.biopha.2026.119679_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40588-025-00251-2","article-title":"DNA Vaccines, an Innovative Vaccine Platform against COVID-19","volume":"2025","author":"Yavuz","year":"2025","journal-title":"Curr. Clin. Micro Rpt"},{"issue":"7838","key":"10.1016\/j.biopha.2026.119679_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2026.119679_bib15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","article-title":"A thermostable, closed SARS-CoV-2 spike protein trimer","volume":"27","author":"Xiong","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6510","key":"10.1016\/j.biopha.2026.119679_bib16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.biopha.2026.119679_bib17","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"27","key":"10.1016\/j.biopha.2026.119679_bib18","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.biopha.2026.119679_bib19","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119679_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119679_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00144-1","article-title":"The SARS-CoV-2 furin cleavage site: natural selection or smoking gun?","volume":"4","author":"Lubinski","year":"2023","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib22","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1080\/10717544.2022.2118398","article-title":"Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real-time cell analysis","volume":"29","author":"Yildiz Pekoz","year":"2022","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119679_bib23","first-page":"493","article-title":"A simple method of estimating fifty-percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64690-5","article-title":"Immunogenicity and protection efficacy of a COVID-19 DNA vaccine encoding spike protein with D614G mutation and optimization of large-scale DNA vaccine production","volume":"14","author":"G\u00fcl","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119679_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/0471140864.ps1003s00","article-title":"One-dimensional electrophoresis using nondenaturing conditions","author":"Gallagher","year":"1995","journal-title":"Curr. Protoc. Proteins Sci. Chapter 10 Unit. 10. 3."},{"key":"10.1016\/j.biopha.2026.119679_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"17","key":"10.1016\/j.biopha.2026.119679_bib27","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2008.02.033","article-title":"The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2026.119679_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jviromet.2013.06.034","article-title":"Real-time cell analysis--a new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activity","volume":"193","author":"Teng","year":"2013","journal-title":"J. Virol. Methods"},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031965","article-title":"Novel, real-time cell analysis for measuring viral cytopathogenesis and the efficacy of neutralizing antibodies to the 2009 influenza A (H1N1) virus","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS. One"},{"issue":"12","key":"10.1016\/j.biopha.2026.119679_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295594","article-title":"Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants","volume":"18","author":"Kim","year":"2023","journal-title":"PLoS. One"},{"issue":"10","key":"10.1016\/j.biopha.2026.119679_bib32","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202215821","article-title":"A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells","volume":"14","author":"Appelberg","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119679_bib33","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.vaccine.2024.01.065","article-title":"Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer","volume":"42","author":"Sood","year":"2024","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.biopha.2026.119679_bib34","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.vaccine.2006.10.060","article-title":"GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine","volume":"25","author":"D\u00f6\u015fkaya","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2026.119679_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105016","article-title":"GRA8 DNA vaccine formulations protect against chronic toxoplasmosis","volume":"158","author":"Karakavuk","year":"2021","journal-title":"Microb. Pathog."},{"issue":"16","key":"10.1016\/j.biopha.2026.119679_bib36","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.vaccine.2022.03.014","article-title":"Immunogenicity of a xenogeneic multi-epitope HER2+ breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205","volume":"40","author":"G\u00fcl","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-14988-9","article-title":"Recombinant ROP6 protein expressed in Saccharomyces cerevisiae INVSc1 cells induced strong immune response and provided significant protection against toxoplasmosis","volume":"15","author":"Karakavuk","year":"2025","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.biopha.2026.119679_bib38","doi-asserted-by":"crossref","first-page":"11957","DOI":"10.3390\/ijms241511957","article-title":"Therapeutic Effect of C-Vx Substance in K18-hACE2 Transgenic Mice Infected with SARS-CoV-2","volume":"24","author":"Ulbegi Polat","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2026.119679_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202200804","article-title":"Investigation of the Antiviral Effects of Saussurea lappa Root Extract against SARS-CoV-2 Virus","volume":"67","author":"Ulbegi Polat","year":"2023","journal-title":"Mol. Nutr. Food Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"6501","key":"10.1016\/j.biopha.2026.119679_bib41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119679_bib42","doi-asserted-by":"crossref","first-page":"m4704","DOI":"10.1136\/bmj.m4704","article-title":"Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study","volume":"371","author":"Wang","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.biopha.2026.119679_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab104","article-title":"Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152\/Covaxin","volume":"28","author":"Yadav","year":"2021","journal-title":"J. Travel. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib44","first-page":"72","article-title":"COVID-19 Vaccines: An Overview of Different Platforms","volume":"9","author":"Kudlay","year":"2022","journal-title":"Bioeng. (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2026.119679_bib45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119679_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.18388\/abp.2007_3251","article-title":"pVAX1 plasmid vector-mediated gene transfer of soluble TRAIL suppresses human hepatocellular carcinoma growth in nude mice","volume":"54","author":"Zhang","year":"2007","journal-title":"Acta Biochim. Pol."},{"issue":"50","key":"10.1016\/j.biopha.2026.119679_bib47","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"VRC 301 Study Team. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.biopha.2026.119679_bib48","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"301","key":"10.1016\/j.biopha.2026.119679_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib50","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119679_bib51","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1038\/ncomms8712","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"issue":"6982","key":"10.1016\/j.biopha.2026.119679_bib52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"issue":"6505","key":"10.1016\/j.biopha.2026.119679_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"6452","key":"10.1016\/j.biopha.2026.119679_bib54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"VRC 317 Study Team. A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41392-020-00365-7","article-title":"SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic","volume":"5","author":"Ismail","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119679_bib56","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026153118","article-title":"A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike","volume":"118","author":"Lu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2026.119679_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/vaccines9040307","article-title":"Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates","volume":"9","author":"Seo","year":"2021","journal-title":"Vaccin. (Basel)"},{"issue":"33","key":"10.1016\/j.biopha.2026.119679_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2201616119","article-title":"A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.biopha.2026.119679_bib59","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14760584.2021.1987223","article-title":"DNA vaccines for SARS-CoV-2: toward third-generation vaccination era","volume":"20","author":"Chavda","year":"2021","journal-title":"Expert. Rev. Vaccin."},{"issue":"10","key":"10.1016\/j.biopha.2026.119679_bib60","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4161\/hv.24702","article-title":"Tolerability of intramuscular and intradermal delivery by CELLECTRA(\u00ae) adaptive constant current electroporation device in healthy volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.biopha.2026.119679_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/1469-0691.12553","article-title":"A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation","volume":"20","author":"Hooper","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"issue":"3","key":"10.1016\/j.biopha.2026.119679_bib62","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"issue":"3","key":"10.1016\/j.biopha.2026.119679_bib63","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ymthe.2022.12.017","article-title":"A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19","volume":"31","author":"Aurisicchio","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119679_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.882918","article-title":"BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults","volume":"13","author":"Seidel","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119679_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248007","article-title":"DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice","volume":"16","author":"Prompetchara","year":"2021","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24519-5","article-title":"Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant","volume":"12","author":"Hayashi","year":"2022","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119679_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2026.119679_bib68","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"7830","key":"10.1016\/j.biopha.2026.119679_bib69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2026.119679_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273430","article-title":"SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice","volume":"17","author":"Lee","year":"2022","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119679_bib71","unstructured":"ATCC Virology Culture Guide. \u3008https:\/\/www.atcc.org\/resources\/culture-guides\/virology-culture-guide\u3009. Last assessed: 19.02.2026."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:31:00Z","timestamp":1784529060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"alternative-id":["S0753332226007158"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119679","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A six-proline stabilized trimeric spike DNA vaccine induces robust immunity and protects against SARS-CoV-2 delta challenge in K18-hACE2 transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119679"}}